Cancer Chemotherapy and Pharmacology

, Volume 62, Issue 5, pp 925–927

Oxaliplatin-induced immune mediated thrombocytopenia

  • Muhammad S. Beg
  • Rami S. Komrokji
  • Kashif Ahmed
  • Malek M. Safa
Short Communication

Abstract

Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.

Keywords

Oxaliplatin Immune Thrombocytopenia 

References

  1. 1.
    Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Int Organ Cancer Chronother Lancet 350:681–686Google Scholar
  2. 2.
    Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Lévi F (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10(6):663–669PubMedCrossRefGoogle Scholar
  3. 3.
    de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947PubMedGoogle Scholar
  4. 4.
    Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH (2006) Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 81:193–196PubMedCrossRefGoogle Scholar
  5. 5.
    Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R (2004) FDA drug approval summaries: oxaliplatin. Oncologist 9:8–12PubMedCrossRefGoogle Scholar
  6. 6.
    Taleghani BM, Meyer O, Fontana S, Ahrens N, Novak U, Borner MM, Salama A (2005) Oxaliplatin-induced immune pancytopenia. Transfusion 45(5):704–708PubMedCrossRefGoogle Scholar
  7. 7.
    Dold FG, Mitchell EP (2003) Sudden-onset thrombocytopenia with oxaliplatin. Ann Intern Med 139(2):E156PubMedGoogle Scholar
  8. 8.
    Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, Mouzaki A, Kalofonos HP (2004) Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage, and hemolysis. Oncology 67(2):179–182PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Muhammad S. Beg
    • 1
  • Rami S. Komrokji
    • 1
  • Kashif Ahmed
    • 1
  • Malek M. Safa
    • 1
    • 2
  1. 1.Department of MedicineUniversity of CincinnatiCincinnatiUSA
  2. 2.Hematology/Oncology Fellowship ProgramUniversity of Cincinnati/Barrett Cancer CenterCincinnatiUSA

Personalised recommendations